EP0524254A1 - A binary genetic system to control expression of a transgene in a transgenic animal - Google Patents
A binary genetic system to control expression of a transgene in a transgenic animalInfo
- Publication number
- EP0524254A1 EP0524254A1 EP91908138A EP91908138A EP0524254A1 EP 0524254 A1 EP0524254 A1 EP 0524254A1 EP 91908138 A EP91908138 A EP 91908138A EP 91908138 A EP91908138 A EP 91908138A EP 0524254 A1 EP0524254 A1 EP 0524254A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- animal
- protein
- transgene
- transactivator
- vertebrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 108
- 108700019146 Transgenes Proteins 0.000 title claims description 96
- 230000009261 transgenic effect Effects 0.000 title claims description 61
- 230000014509 gene expression Effects 0.000 title claims description 53
- 230000002068 genetic effect Effects 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 34
- 230000027455 binding Effects 0.000 claims abstract description 33
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 25
- 108091023040 Transcription factor Proteins 0.000 claims description 109
- 102000040945 Transcription factor Human genes 0.000 claims description 103
- 102100039556 Galectin-4 Human genes 0.000 claims description 84
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 70
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 20
- 230000000869 mutational effect Effects 0.000 claims description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 18
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 15
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 15
- 239000003623 enhancer Substances 0.000 claims description 14
- 230000004568 DNA-binding Effects 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 9
- 230000013011 mating Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 230000002939 deleterious effect Effects 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 2
- 210000000748 cardiovascular system Anatomy 0.000 claims description 2
- 210000000750 endocrine system Anatomy 0.000 claims description 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 210000000777 hematopoietic system Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 210000004994 reproductive system Anatomy 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 27
- 238000011830 transgenic mouse model Methods 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 14
- 108010000521 Human Growth Hormone Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102000002265 Human Growth Hormone Human genes 0.000 description 12
- 239000000854 Human Growth Hormone Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 239000003298 DNA probe Substances 0.000 description 8
- 108020003215 DNA Probes Proteins 0.000 description 7
- 229910002056 binary alloy Inorganic materials 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000003079 salivary gland Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000206602 Eukaryota Species 0.000 description 4
- 238000011771 FVB mouse Methods 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002390 hyperplastic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 108010055905 alpha-Crystallin A Chain Proteins 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 101150022075 ADR1 gene Proteins 0.000 description 1
- 101800000112 Acidic peptide Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 101710088570 Flagellar hook-associated protein 1 Proteins 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150065703 LAC9 gene Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101710096690 Mating-type protein ALPHA2 Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100293261 Mus musculus Naa15 gene Proteins 0.000 description 1
- 101150082943 NAT1 gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010046983 Ribonuclease T1 Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000003670 sublingual gland Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/70—Vector systems having a special element relevant for transcription from fungi
- C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Definitions
- the field of the invention is transgenic animals.
- transgenic animals particularly those that may be used as disease models
- survival and breeding of transgenic animals is often precarious due to the deleterious effect of the expressed transgene.
- the animals may develop tumors before they reach reproductive age.
- an animal having an immune system that is defective because of the presence of a toxic gene may be difficult to maintain because of its susceptibility to infectious disease.
- Other transgenes may render the transgenic animal sterile.
- One method of ensuring maintenance of a strain bearing a particular toxic transgene is to reduce the fixed level of expression of the transgene to a level tolerated by the animal. This has been accomplished in one transgenic system by incorporating one or more copies of a lac operator-like sequence into the promoter region of the transgene, resulting in a permanent, dose-dependent attenuation of expression of that
- transgene (Tepper et. al., manuscript in preparation). Also, the choice of the promoter region itself offers some degree of control over the particular tissue(s), and, to a very limited extent, the particular
- transgene fused to a murine ⁇ A-crystallin promoter region was detected solely in eye lens tissue of an animal bearing the transgene (Overbeek et al., Proc.
- pancreatic aciner cells beginning several days before birth (Ornitz et al.,
- the binary system disclosed herein allows the indefinite maintenance of a potentially deleterious "target" transgene in a line of transgenic animals by fusing to the target transgene a promoter containing one or more expression control elements [a DNA sequence such as an enhancer or an upstream activating sequence
- transactivator protein refers to any polypeptide, naturally occurring or otherwise, which is capable of binding to a specific DNA sequence (such as a UAS) in a gene, and thereby increasing the level of transcription of (or “transactivating") that gene.
- a transactivator set An animal having a
- transactivated target transgene can then be generated at will, by simply mating an animal bearing the silent target transgene with a second transgenic animal bearing a transgene encoding a transactivator protein capable of activating expression of the target transgene, yielding offspring some proportion of which bear a copy of both of the two transgenes (i.e., they are "bi-transgenic"). If the first mono-transgenic parent is homozygous for the target transgene and the second parent is homozygous for the transactivator transgene, then 100% of their offspring will be bi-transgenic.
- the target transgene will be expressed in any tissues of these bi-transgenic offspring in which the appropriate transactivator protein is present at a sufficiently high level: thus, the promoter region associated with the transactivator transgene dictates not only the spactial and temporal pattern of expression of the transactivator transgene, but also, indirectly, the pattern of expression of the target transgene in these bi-transgenic animals.
- the failure of such bi-transgenic animals to survive and/or reproduce (owing to the toxic effects of the expressed target transgene) is immaterial, as new bi-transgenic animals can be easily generated as needed from the viable stocks of mono-transgenic animal lines.
- transactivator protein but a different promoter sequence dictating a different pattern of activator transgene expression.
- the particular pattern of expression desired for a given target transgene can then be
- transactivator transgenic line and mating an animal from that line with an animal bearing the target transgene.
- transactivator proteins also referred to as "transcriptional factors”
- yeast such as Saccharomyces cerevisiae
- transactivator protein-binding DNA sequence incorporated into the target transgene not be recognized and bound by any transactivator proteins (or other DNA-binding proteins) endogenous to the trangenic animal's species, which proteins might be capable of switching on
- the transactivator set is ideally derived from an organism that is evolutionarily far removed from the species of the transgenic animal.
- the transgenic animal is a
- the organism from which the transactivator set is derived could be an invertebrate animal (such as an insect), a plant, a single-celled eukaryote, or a prokaryote.
- the transactivator-binding DNA sequence utilized can be a naturally-occurring sequence (such as any one of the four illustrated in Fig. 2A), or can be a variation on a naturally-occurring sequence (such as in Fig. 2B) which in practice functions to bind the
- the transactivator protein can be a naturally-occurring protein; a
- transactivator protein reflecting a mutation (such as a deletion) in the gene encoding the protein, but which retains at least some of the transactivation activity of the naturally-occurring protein; a chimeric protein combining, for example, the DNA-binding domain of one protein (which can be any type of transcription-control protein which binds DNA: e.g., a transactivator protein or a repressor protein such as the E. coli lac
- GAL4 is one of several known yeast transactivator proteins. Examples of mutational variants of the GAL4 transactivator protein are shown in Fig. 1; either the ⁇ -galactosidase method of Ma and
- transactivator proteins for use in the binary system of the invention, because the former are likely to include signal sequences which target their delivery to the nucleus of the cell for binding to genomic DNA.
- the transactivator protein is from a eukaryotic organism
- a promoter region to which the transactivator protein is known to bind can be excised from its gene and transferred in its entirety into the target transgene to serve as the promoter of the transgene, eliminating the necessity to locate and characterize the precise sequence of DNA to which the transactivator protein binds.
- This strategy would not be expected to work with a prokaryotic promoter, which would lack many essential features of a functional eukaryotic promoter, such as enhancer elements with position independence.
- prokaryotic transactivator set employed in the binary trangenic animal of the invention, if (1) the prokaryotic transactivator protein is expressed in sufficient amounts, or is engineered to include a nuclear transport signal, such that enough of it enters the nucleus to stimulate transcription of the target gene; and (2) the relevant prokaryotic transactivator-protein-binding sequence is known, and can be inserted into a target gene which has a promoter that can function properly in a transgenic animal.
- the invention features a transgenic non-human vertebrate animal having cells containing a transgene (the "transactivator transgene") encoding a non-vertebrate transactivator protein (i.e., the animal is transgenic for that transgene).
- the transactivator transgene encoding a non-vertebrate transactivator protein (i.e., the animal is transgenic for that transgene).
- transgene is defined as a piece of DNA which is inserted by artifice (i.e., by a means other than sexual propagation) into a cell, and becomes part of the genome of the animal which develops from that cell.
- a transgene may be a gene which is partly or entirely heterologous (i.e., foreign) to the transgenic animal, or alternatively may represent a gene homologous to a natural gene of the transgenic animal, but which is inserted into the animal's genome at a location which differs from that of the natural homolog.
- a "transgenic animal” is an animal having cells that contain a
- transgene which transgene was introduced into the animal, or an ancestor of the animal, at an embryonic stage.
- embryonic stage is meant any point from the moment of conception (e.g., as where the sperm or egg bears the transgene) throughout all of the stages of embryonic development of the fetus, and preferably refers to a stage within the first eight days following conception.
- non-vertebrate transactivator protein is meant a transactivator protein which occurs naturally in a non-vertebrate organism [e.g., a prokaryote, a
- single-celled eukaryote such as yeast
- a plant of any type such as an animal (such as an insect) other than a vertebrate]
- an animal such as an insect
- a virus other than one which infects vertebrate animals
- a genetically engineered transactivator protein including a mutational variant of a naturally-occurring
- transactivator protein that does not bind detectably to the genomic DNA of a non-transgenic animal of the same species as the transgenic animal of the invention, but which does bind to the DNA sequence to which the
- the invention also features a non-human vertebrate animal which is transgenic for a target transgene that includes a DNA sequence capable of binding the non-vertebrate transactivator protein.
- the DNA sequence is about 9-35 nucleotides in length; both the transactivator transgene and the target transgene occur in the same (bi- transgenic) animal; and binding by the transactivator protein to the target transgene increases the level of expression of the target transgene: preferably at least 10-fold, and more preferably at least 100 fold, compared to the level of target transgene expression in an animal transgenic only for the target transgene.
- the target gene is expressed either not at all, or at a level so low that it approaches the lower limit of detection.
- the transgenic animal is a mammal (e.g., a rodent such as a mouse); and the transactivator protein contains a DNA-binding domain (i.e., the portion of the transactivator protein which is involved in recognizing and binding to a specific DNA sequence) of a transactivator protein derived from a single-celled organism (i.e., a prokaryote, or a lower eukaryote such as a yeast of any kind, including but not limited to
- transcription-control proteins covers both positive (e.g., transactivator) and negative (e.g., repressor) transcription-regulating proteins which affect transcription of a gene by binding to a specific DNA sequence associated with that gene.
- transactivator proteins useful in the binary transgenic system of the invention include the many known yeast transactivator proteins, such as GCN4 protein, MAT ⁇ 2 protein, HAP1 protein, PPR1
- transactivator protein is herein defined as a
- transactivator protein can be determined by deletion analysis (as by the method of Ma and Ptashne, 1987a) or by extrapolation from the information known about GAL4 and other transactivator proteins (e.g., the N-terminal location and overall positive charge of the DNA-binding domain).
- the transactivator transgene contains a heterologous promoter region (defined as a 5' untranslated region, including enhancer, which is capable of driving transcription of the transactivator transgene in vivo and is derived from a gene or genes other than the natural gene which encodes the
- a particular heterologous promoter region is dictated by the spatial and temporal pattern of expression that is desired for the transgene, and could include a promoter region which predominantly directs expression in, for example, the reproductive system (e.g., breast, ovary, or testes); the musculoskeletal system (e.g., muscle or joint tissue); the cardiovascular system (e.g., capillaries or heart); the respiratory system (e.g., lung or nasal passages); the urological system (e.g., kidney or bladder); the gastrointestinal system (e.g., pancreas, liver, or intestines); the immune system (e.g., thymus, spleen, or circulating immunological cells); the reproductive system (e.g., breast, ovary, or testes); the musculoskeletal system (e.g., muscle or joint tissue); the cardiovascular system (e.g., capillaries or heart); the respiratory system (e.g., lung or nasal passages); the urological system (
- endocrine system e.g., pituitary, gonads, and thyroid
- the nervous system e.g., neurons
- hematopoietic system e.g., bone marrow and peripheral blood.
- hematopoietic system e.g., bone marrow and peripheral blood.
- the ⁇ A-crystallin promoter region (including its associated enhancer or another functional enhancer), the ⁇ A-crystallin promoter region
- Viral promoters (such as MMTV LTR and the CMV LTR) which direct expression of viral (or host) genes in specific tissues are other possible choices.
- the DNA sequence to which the transactivator protein binds is a transactivator
- transactivator protein is GAL4 protein or another protein which binds specifically to a GAL4 protein-binding DNA sequence (such as a mutational variant of GAL4 protein)
- the transactivator- binding DNA sequence in the target transgene is GAL4 protein or another protein which binds specifically to a GAL4 protein-binding DNA sequence (such as a mutational variant of GAL4 protein).
- the invention also includes a vertebrate cell (preferably a mammalian cell that is not a human cell) containing a stably-integrated foreign gene which includes a DNA sequence capable of binding a non- vertebrate transactivator protein, and a method of increasing the level of expression of that foreign gene in the cell.
- stably-integrated foreign gene is meant a gene which is not endogenous (or a portion of which is not endogenous) to the animal species from which the cell is derived, or which is inserted into the cell's genome at a site that differs from its
- the non-vertebrate transactivator protein is directly incorporated into the cell (as by fusion with liposomes carrying the transactivator protein), or is encoded by a second foreign gene which has been introduced into the cell; it is a protein which is naturally produced by a single-celled organism such as a prokaryote or, more preferably, a yeast (or a mutational variant of such a protein); and when bound to the transactivator
- transactivator protein protein-binding DNA sequence of the foreign gene, it increases the level of expression of the foreign gene in the cell.
- transactivator protein examples include all of the examples referred to above.
- the invention provides a method of increasing the level of expression of a target transgene in a line of transgenic animals (e.g., vertebrate animals such as mammals, and in particular, rodents, including mice), which method involves mating a first animal from that line of transgenic animals with a second animal which bears (i.e., is transgenic for) a second transgene encoding a non-vertebrate transactivator protein that is capable of transactivating expression of the target transgene.
- the level of target transgene expression can be increased in an animal transgenic for the target transgene by infecting the animal with a virus, the genome of which has been altered to encode the non-vertebrate transactivator protein. This method would permit targeting of a specific tissue for
- the target transgene is the Maloney Murine Leukemia Virus (MoMuLV).
- MoMuLV Maloney Murine Leukemia Virus
- transactivator protein-binding DNA sequence such as one of those described above
- the transactivator protein is preferably one of those described above.
- Fig. 1 is a representation of a series of deletion mutational variants of the yeast GAL4 protein which were tested for their ability to activate
- transactivator protein-binding sequence (A), (B), and (C): relative efficiency of transactivation is
- GAL4/236 residues 1-147 and 768-881
- pAG242 encodes GAL4 residues 1-238 and 768-881 (adapted from Figure 2 of Kakidani and Ptashne, 1988).
- Fig. 2 is an illustration of (A) four naturally-occurring S.cerevisiae GAL4 transactivator- protein-binding DNA sequences, (B) a synthetic 17 bp oligodeoxynucleotide capable of binding the yeast GAL4 transactivator sequence , and (C) a second synthetic 17 bp oligodeoxynucleotide (termed a "Sea I GAL4 binding site" because it contains a Sea I restriction site;
- Fig. 3 is a representation of (A) the MMTV LTR/GAL4 transactivator gene described in Example 2; (B) the int-2 target gene described in Example 1; and (C) an expanded view of the UAS/elastase promoter of the target gene.
- Fig. 4 is an illustration of the structure of
- Fig. 5 is an autoradiogram of a thin layer chromatograph separating the species of chloramphenicol which result from the CAT assay; unacetylated
- chloramphenicol remains near the left of each lane, while acetylated and bi-acetylated chloramphicol migrate toward the right.
- A, B, and C represent three
- Fig. 6 is a Northern blot analysis of RNA from various tissues of mono- and bi-transgenic mice, probed with (A) a GAL4 cDNA probe, and (B) an int-2 DNA probe.
- Fig. 7 is (A) an illustration of the portion of the UAS/Int-2 transgene spanned by the 330 nt DNA probe used for ribonuclease protection analysis, and the portion of the int-2 mRNA which is protected from RNase digestion by that 330 nt probe; and (B) ribonuclease protection analysis of RNA derived from various tissues of mono- and bi-transgenic mice.
- a target gene was engineered to include, from the 5' end, a rat elastase promoter (but not its enhancer), into which were inserted four copies of a GAL4-binding oligonucleotide (UAS G ); mouse int-2 cDNA; and a human growth hormone (hGH) gene.
- UAS G GAL4-binding oligonucleotide
- hGH human growth hormone
- Example 2 sets forth the construction of the transactivator gene, in which a mouse mammary tumor virus (MMTV) long terminal repeat (LTR) and 600 bp of 5' untranslated c-HA-ras DNA were fused to a sequence encoding a biologically-active deletion mutational variant of GAL4 (GAL4/236), and finally to an SV40 splice/polyadenylation signal
- Example 4 Construction of the target gene
- a plasmid (the "target plasmid") containing the target gene was constructed as follows:
- This promoter was selected because, in the absence of a functional enhancer element, a transgene bearing this promoter is not expressed in transgenic mice, but can be activated by any of a number of heterologous enhancers (Ornitz et al., Molec. Cell. Biol. 7:3466-3472, 1987).
- This UAS/elastase promoter was then fused upstream of the 2.1 kb human growth hormone (hGH) gene (Seeburg, DNA 1:239-249, 1982).
- This plasmid (pUAS/elastase/hGH; Fig. 4A) was used as the target plasmid for one of the in vitro experiments described in Example 3.
- Example 5 For use in generating the transgenic mouse of Example 5, it was further modified, as follows: a 2 kb Hind III fragment containing the int-2 gene (Dixon et al., Molec. Cell. Biol. 9:4896-4902, 1984; Muller et al., EMBO J. in press, 1990) was blunt ended, ligated to Bgl II linkers, cut with Bgl II, and cloned into the Bamh I site of UAS/elastase/hGH to yield the target plasmid shown in Fig. 3B.
- a 2 kb Hind III fragment containing the int-2 gene (Dixon et al., Molec. Cell. Biol. 9:4896-4902, 1984; Muller et al., EMBO J. in press, 1990) was blunt ended, ligated to Bgl II linkers, cut with Bgl II, and cloned into the Bamh I site of UAS/
- Int-2 is a murine gene encoding a protein, related to fibroblast growth factors, that is implicated in both murine and human breast neoplasia (Dickson et al., Cell 37:529-536, 1984). Normally expressed in specific patterns during early embryonic development, int-1 has a known phenotype when overexpressed in breast and prostate tissues of transgenic mice (Muller et al., 1990).
- the hGH portion of this construct provides introns and polyadenylation sequences, and may increase message stability (Palmiter et al., Cell 50:435-443, 1987); however, being downstream of the int-2
- pMMTV-GAL4/236-SV40 (MMTV GAL4, Figure 3A) consists of 2.3 kb of the mouse MMTV LTR and 600 bp of 5' untranslated c-HA-ras (Huang et al., Cell 27:245-255. 1981; Muller et al., Cell 54: 105-115, 1988) fused to a 1 kb Hind III fragment of pAG236 (obtained from Ivan Sodowsky and Mark Ptashne) containing the GAL4/236 gene (Kakidani and Ptashne, Cell 52:161-167, 1988).
- the 3' end of the construct contains the 800 bp SV40 splice/polyadenylation signal (Seed, Nature 329:840-842, 1987). Also prepared was a control plasmid, pGEM GAL4, in which the GAL4/236 gene has no promoter and thus would not be expressed (Fig. 4D).
- CMV cytomegalovirus
- pCMV GAL4, Fig. 4E Boshart et al.. Cell 41:521-530, 1985
- an immunoglobulin heavy chain enhancer and promoter pEuPu GAL4, Fig. 4C; Tepper et al., manuscript in preparation; provided by E. Schmidt.
- Example 1 the target gene utilized for these in vitro experiments was pGSBCAT (Fig. 4B; provided by Ivan
- the plasmids were purified once on CsCL gradients, and then simultaneously electroporated into approximately 10 6 cells of a plasmacytoma cell line, J558L, at a ratio of 18 ⁇ g pG5BCAT to 2 ⁇ g
- pGEM GAL4 which contains a GAL4/236-encoding sequence with no promoter or transactivator-binding sites
- Fig. 4D pCMV GAL4 (Fig. 4E); or pEuPu GAL4 (Fig. 4C)
- Fig. 4D protein extracts of the transiently-transfected cell samples were prepared and assayed for CAT activity.
- pGEM GAL4 tran ⁇ fections from any of the three pools of cells: the promoterless GAL4/236 gene in pGEM GAL4 is presumably not expressed, resulting in no GAL4/236 protein to transactivate expression of the CAT gene.
- the UAS/elastase/hGH plasmid described in Example 1 was substituted for the pGSBCAT target plasmid.
- Cells which were stably transfected with the UAS/elastase/hGH gene produced detectable hGH only if they had also been transiently transfected with a plasmid encoding and expressing GAL4/236 protein.
- a Ncol-Spel restriction fragment containing the MMTV GAL4/236 gene (Fig. 3A) was produced by digesting pMMTV GAL4 with Ncol and Spel, followed by agarose gel electrophoresis and electroelution of the excised band.
- the DNA fragment was microinjected into fertilized ova of inbred FVB mice (Taconic Farms, Germantown, NY) by standard techniques (Brinster et al., Proc. Nat1. Acad. Sci. USA 82:4438-4442, 1985; see also U.S. Patent
- hybridizing tail DNA with a 1 kb DNA probe derived from GAL4 cDNA, or a 0.8 kb probe derived from SV40
- RV splice/polyadenylation signal DNA
- FIG. 6A demonstrates that the GAL4/236 gene is expressed in certain tissues of mice bearing the MMTV GAL4/236 transgene (mice 1 , 2 , and 4 of Fig . 6A).
- the prominent 2.4 kb band is the predicted size for the MMTV GAL4/236 mRNA.
- the GAL4-specific DNA probe hybridized to RNA samples from breast tissue ("Br"), salivary gland (“Sa”) and epididymis ("Ep”), but not to samples from liver (“Li”), kidney (“Ki”), or spleen (“Sp”) of these
- Hind III yielded a 4.5 kb UAS/int-2 gene-containing DNA fragment that was isolated by electroelution from a band excised from an agarose electrophoresis gel. This fragment was microinjected into fertized FVB mouse ova as described above; six founder mice were identified by hybridization of tail DNA with a 1 kb hGH gene-specific DNA probe. Transgenic mouse lines derived from these six founder mice (designated DG, DH, DX, DY, DZ, and OA) appear to be fertile and free of pathology by both gross and histological examination.
- Fig. 6B wherein the mouse designated "3" was a pregnant DZ mono-transgenic female, while mouse 5 was a virgin DZ mono-transgenic female.
- RNase protection analysis [performed as described by Melton et al. (Nucl. Acids Res. 12:7053-7056, 1984) by hybridizing 40 ⁇ g of total RNA from each specified tissue of mice 3 and 5 (and 10-20 ⁇ g RNA from each of mice 1, 2, and 4) to a 330 nt antisense riboprobe derived from the 5' end of the int-2 target gene (shown with the expected 188 nt protected fragment in Fig. 7A), digesting with RNase A and RNase T1 (SIGMA), and electrophoresing on 6%
- mice from each of the six target transgenic lines were bred to mice from the "RV" transactivator line.
- Bi-transgenic offspring were identified by
- GAL4/236 was expressed at high levels in breast and salivary glands of both virgin and pregnant female bi-transgenic mice, and in salivary glands and
- int-2 mRNA is present at high levels in these tissues of bi-transgenic animals.
- the prominent 3 kb band is the predicted size for an int-2/hGH mRNA.
- Fig. 7A an RNase protection probe overlapping the elastase promoter and 5' int-2 sequences was hybridized to RNA from several tissues of these mice 1-5.
- Fig. 7B shows evidence of 185 nt and 188 nt protected fragments in tissues from breast tissue, salivary gland and epididymis of
- Control mono-transgenic mice containing only the int-2 target gene appear, upon gross examination, to be normal.
- Whole mount preparations from breast tissue of int-2 mice are indistinguishable from those of normal, non-transgenic, age-matched FVB mice.
- the mammary tissue of virgin bi-transgenic females appears normal, whereas pregnant bi-transgenic mice develop massively enlarged mammary glands owing to int-2 gene expression and increased levels of certain hormones during pregnancy. Within 2 weeks postpartum, the mammary glands regress substantially; however, histological analysis of the glandular tissue at autopsy shows that it remains abnormally hyperplastic.
- Histologic sections from breast tissue of virgin bi-transgenic females demonstrate mammary ductal structures that are mildly hyperplastic, with some epithelial cells containing lipid droplets
- mice from several of the target lines develop epididymal and prostate hyperplasia (Table 1). Although these mice are able to mate, they fail to sire any offspring even after multiple confirmed vaginal plugs.
- bi-transgenic animals exhibit parotid and sublingual gland enlargement. Histologic analysis reveals
- the binary transgenic system of the invention provides a means for indefinitely maintaining a silent but potentially deleterious transgene in a viable animal line, and yet producing, at will, an offspring of that line in which the transgene is expressed.
- This system is useful for supplying animals for use as models of human diseases (e.g., for testing proposed new
- the binary system can be applied to the development of animals to serve as a source of, for example, medically-important human proteins or transplantable organs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Cette invention se rapporte à un animal vertébré à gènes mutants ayant des cellules contenant un gène mutant qui (1) code une protéine transactivante d'invertébré ou (2) contient une séquence d'ADN capable de se lier avec une protéine transactivante d'invertébré, et un procédé pour utiliser un tel animal.This invention relates to a mutant gene vertebrate animal having cells containing a mutant gene which (1) encodes an invertebrate transactivating protein or (2) contains a DNA sequence capable of binding with an invertebrate transactivating protein , and a method for using such an animal.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50231590A | 1990-03-30 | 1990-03-30 | |
US502315 | 2000-02-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0524254A1 true EP0524254A1 (en) | 1993-01-27 |
EP0524254A4 EP0524254A4 (en) | 1993-04-28 |
Family
ID=23997263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19910908138 Withdrawn EP0524254A4 (en) | 1990-03-30 | 1991-03-22 | A binary genetic system to control expression of a transgene in a transgenic animal |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0524254A4 (en) |
JP (1) | JPH05505727A (en) |
CA (1) | CA2077686A1 (en) |
WO (1) | WO1991015111A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714345A (en) * | 1990-12-24 | 1998-02-03 | Pharmaceutical Proteins Limited | Increased expression of a gene by a second transferred mammary gland specific sequence transgenic |
GB9028062D0 (en) * | 1990-12-24 | 1991-02-13 | Agricultural & Food Res | Production of transgenic animals |
GB2337519A (en) * | 1998-05-19 | 1999-11-24 | Univ Bristol | Transgenic mammal comprising specific means for regulation of transgene expression |
US7005423B1 (en) | 1999-07-02 | 2006-02-28 | Devgen Nv | Characterization of gene function using double stranded RNA inhibition |
GB9827152D0 (en) * | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
US6639121B1 (en) | 1999-07-29 | 2003-10-28 | Dana-Farber Cancer Institute, Inc. | Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo |
-
1991
- 1991-03-22 WO PCT/US1991/001946 patent/WO1991015111A1/en not_active Application Discontinuation
- 1991-03-22 EP EP19910908138 patent/EP0524254A4/en not_active Withdrawn
- 1991-03-22 CA CA 2077686 patent/CA2077686A1/en not_active Abandoned
- 1991-03-22 JP JP91507590A patent/JPH05505727A/en active Pending
Non-Patent Citations (2)
Title |
---|
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 88, no. 3, 1 February 1991, WASHINGTON US pages 698 - 702 ORNITZ, D.M. ET AL. 'Binary systen for regulating transgene expression in mice: targetting int-2 gene expression with yeast GAL4/UAS control element' * |
See also references of WO9115111A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2077686A1 (en) | 1991-10-01 |
WO1991015111A1 (en) | 1991-10-17 |
EP0524254A4 (en) | 1993-04-28 |
JPH05505727A (en) | 1993-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220256819A1 (en) | Chimeric gene constructs for generation of fluorescent transgenic ornamental fish | |
Ornitz et al. | Binary system for regulating transgene expression in mice: targeting int-2 gene expression with yeast GAL4/UAS control elements. | |
Caterina et al. | Cloning and functional characterization of LCR-F1: a bZIP transcription factor that activates erythroid-specific, human globin gene expression | |
US5545808A (en) | Transgenic salmonid fish expressing exogenous salmonid growth hormone | |
JP2863789B2 (en) | DNA sequence in proteins expressed in the mammary gland for efficient secretion | |
Lira et al. | Identification of rat growth hormone genomic sequences targeting pituitary expression in transgenic mice. | |
DiMattia et al. | The Pit-1 gene is regulated by distinct early and late pituitary-specific enhancers | |
US5648243A (en) | Human serum albumin expression construct | |
CA2182958A1 (en) | Mammal with enhanced liver expression of a transgene | |
CA2293722A1 (en) | Transgenic fish with tissue-specific expression | |
US5476926A (en) | Adipocyte-specific DNA sequences and use thereof in the production of transgenic animals exhibiting altered fat tissue metabolism | |
WO1994013273A1 (en) | Sequences useful for obtaining high level, copy number-dependent, essentially position-independent gene expression in cellular and transgenic systems | |
Allison et al. | Tissue-specific and hormonal regulation of the gene for rat prostatic steroid-binding protein in transgenic mice | |
US5789651A (en) | Isolation and characterization of Agouti: a diabetes/obesity related gene | |
Moav et al. | Regulation of expression of transgenes in developing fish | |
EP0524254A1 (en) | A binary genetic system to control expression of a transgene in a transgenic animal | |
Gerlinger et al. | B-lymphocyte targeting of gene expression in transgenic mice with the immunoglobulin heavychain enhancer | |
US5082779A (en) | Method of directing transgenic expression in animals using a prolactin promoter | |
Neznanov et al. | Contrasting effects of the SATB1 core nuclear matrix attachment region and flanking sequences of the keratin 18 gene in transgenic mice. | |
EP0648841B1 (en) | Genomic DNA of human Cholesterol 7alpha-hydroxylase and methods for using it | |
WO1996005299A1 (en) | Dna vector for bone-specific gene expression | |
Fine | Expression of Escherichia coli beta-galactosidase in transgenic mice: An approach to cell lineage analysis | |
US20020023276A1 (en) | Dna sequences to target proteins to the mammary gland for efficient secretion | |
MXPA98004115A (en) | Purification of more elevated order transcription compositions from transgenic animals no huma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19921007 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE FR IT |
|
A4 | Supplementary search report drawn up and despatched | ||
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): DE FR IT |
|
17Q | First examination report despatched |
Effective date: 19950316 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19950727 |